AMNEAL PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Defined Contribution Plan, Cost of $11.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2018-12-31 was $400.00K, a 63.64% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2018-09-30 was $2.30M, a 228.57% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2018-06-30 was $1.30M, a 116.67% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for the quarter ending 2017-12-31 was $1.10M.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $11.30M, a 22.83% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $9.20M, a 7.07% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $9.90M, a 4.21% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $9.50M, a 6.74% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $11.30M 10-K · filed 2026-02-27 | ||||
| 2024-12-31 | $9.20M 10-K · filed 2026-02-27 | ||||
| 2023-12-31 | $9.90M 10-K · filed 2026-02-27 | ||||
| 2022-12-31 | $9.50M 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $8.90M 10-K · filed 2024-03-14 | $9.00M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $7.70M 10-K · filed 2023-03-03 | $8.00M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $7.00M 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.70M derived: sum of 2 quarters · filed 2021-03-01 | $4.00M derived: sum of 3 quarters · filed 2021-03-01 | $7.00M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $2.30M 10-Q · filed 2018-11-07 | $3.60M derived: sum of 2 quarters · filed 2018-11-07 | $6.60M 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $1.30M 10-Q · filed 2018-08-09 | $4.30M 10-Q · filed 2018-08-09 | |||
| 2017-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.80M derived: sum of 2 quarters · filed 2020-03-02 | $2.40M derived: sum of 3 quarters · filed 2020-03-02 | $3.00M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $700.00K 10-Q · filed 2018-11-07 | $1.30M derived: sum of 2 quarters · filed 2018-11-07 | $1.90M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $600.00K 10-Q · filed 2018-08-09 | $1.20M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $2.00M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |